SureTrader
Interactive Brokers Advertisement
SureTrader
Home > Boards > US OTC > Medical - Drugs >

ViaDerma Inc. (VDRM)

VDRM RSS Feed
Add VDRM Price Alert      Hide Sticky   Hide Intro
Moderator: mick, Clonefan, er111a, GreenBrickRoad, ddtburg, Cryptocol
Search This Board: 
Last Post: 6/24/2017 7:19:41 PM - Followers: 473 - Board type: Free - Posts Today: 0


VDRM

ViaDerma, Inc.

A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.

APPLICATIONS & USAGE

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year
     

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
 

Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744

Email:  info@viadermalicensing.com

LINKS TO:
 

                             Most Recent News    

Most Recent Filings and Disclosures

 

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Verified by Transfer Agent

Authorized Shares: 400,000,000 a/o May 31, 2017

Outstanding Shares: 380,214,603 a/o May 31, 2017

(Restricted 65,575,478 - Unrestriced 314,239,125) a/o May 31, 2017

Held at DTC - N/A

Float: 222,337,825 a/o Jan 25, 2017

Par Value    0.001


-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

$VDRM COULD BE THE pharmacy stock of the year. This stock could run 30,000% here's why.

1) EXTREMELY OVERSOLD and unknown 
2) ONLY 150 MILLION A\S! Makes it the TINIEST FLOAT VS PRICE out of ALL pharmacy stockso in the whole country!
3) Pharmaceutical stocks have the LARGEST PERCENTAGE GAINS OUT OF ALL STOCKS IN THE MARKET on the big boards or the OTHER. 
4) Unusual sudden MASSIVE increase in volume since 3/7/16 LOOK.
5) INSIDERS OWN 75 MILLION SHARES, that's right 75 MILLION!
6) WON AWARD FOR THEIR DRUG
7) After being silent for ages 4 JUICY FILINGS came out in September so something could be up.
8) THEY HAVE A PATENT which big boys have to be eyeing.

VDRM IS A HIDDEN GOLDMINE

THIS IS NOT A REGULAR PENNY STOCK. The LOWEST FLOAT vs price vs ALL PHARMA STOCKS IN THE COUNTRY. BIG BOARD OR OTC LAND. ALL OF THEM. Pharma stocks have the HIGHIGHEST EST percentage gain in big boards or penny stocks

-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

HUGE:
 

VDRM ENTERS MMJ PLAYING FIELD

LOS ANGELES, CA--(Marketwired - November 14, 2016) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, announced today the Patent Pending use of its innovative transdermal system for the delivery of (CBD's) Calanoids and (THC) Tetrahydrocannabinol for the treatment of several diseases. The transdermal system can deliver through topical skin absorption to localized areas and directly into the blood stream. The Patent application using the combination of CBD's and THC with the delivery system was filed in 2014. The Patent Pending transdermal system can deliver medications and nutrients into the body through the skin. For example, a person with a migraine headache can place the CBD and THC combined with the delivery compound and apply to the neck with immediate absorption into the bloodstream through the corroded artery. ViaDerma, Inc. is also in the clinical testing stages of an anti-aging topical solution, topical pain medication, a topical for male-pattern baldness, and a topical designed to boost male libido.

On November 8th, medical and recreational marijuana was passed in several states that voted on medical marijuana provisions, in what is turning out to be, the biggest electoral victory for marijuana reform since 2012. The use of CBD's is known for the reduction of inflammation and for the treatment of several diseases, such as, nicotine addiction, fibromyalgia, Cohn's disease, schizophrenia, migraine headaches, pain management for cancer and Multiple Sclerosis.


 



"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

 
INTELLECTUAL PROPERTY FILED BY DR. CHRIS AYO OTIKO
 PATENTS TRADEMARKS
NAME NUMBER NOTES NAME NUMBER STATUS
2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
VIADERMA'S ANNOUNCED DISTRIBUTORS
Business Name Owner Registered Otiko's Role
BIOGENX
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
TBD
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
TBD CA
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.
 

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

May 03, 2017

OTC Disclosure & News Service

- ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

ViaDerma, Inc. will Vigorously Defend the Company's Patents, Product Line and its Shareholders from the Current Complaint Against the Company

 

The Company plans on vigorously defending a lawsuit filed by Steven Keough in South Dakota that it believes was filed to stall the product launch of the Company's FDA Registered Viabecline. The Company is also evaluating its own claims against Keough and intends on filing its own claims against Keough.

LOS ANGELES, CA--(Marketwired - May 03, 2017) - ViaDerma, Inc. (OTC PINK: VDRM), a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company's legal counsel, Austin Legal Group, will be addressing the complaint filed by Steven J. Keogh in South Dakota Federal Court. The complaint alleges issues dating back to 2011 which the Company believes have been addressed, and the Company is evaluating potential counter claims against the plaintiff. The Company has filed provisional patents on several products, and their pending status has already gone through a screening process by the USPTO.

The Company's President, Dr. Christopher Otiko, stated, "The Company's legal counsel will vigorously defend this civil legal action to protect our shareholders and the Company's patent pending product line. The Company is moving ahead with its aggressive growth plans and plans to complete its initial production of Viabecline topical antibiotic by the end of Q2."

 

RECENT NEWS

06/12/17 - ViaDerma, Inc. Commences First Manufacturing Run And Will Meet the 2nd Quarter Product Distribution Milestone  

05/15/17 - Viaderma, Inc. Recevies Positive Results On Phase I Testing In Canada With Its Proprietary THC delivery and moves to Phase II Trials and Development Of New Products With Its MMJ Technologies 


05/03/17 - ViaDerma, Inc. Will Vigorously Defend The Company's Patents, Product Line, and its Shareholders from current complaint against the company 

04/19/17 - ViaDerma, Inc. Announces its President, Dr. Christopher Otiko's Abstract was Well Received at the DFCON Conference as the Company Completes Final Testing for its FDA Registered Viabecline for Manufacturing in the Next Several Weeks

04/05/17 - ViaDerma, Inc. Enters the Sexual Dysfunction Market & Files with the Food and Drug Administration (FDA) for a New OTC Drug to Conquer Premature Ejaculation for Men

03/20/17 - ViaDerma Receives Provisional Patent Numbers for Its FDA Registered Viabecline and Cannabis Technologies, and Seeks to Distribute its Products with a Management, Marketing and Distribution Company in Canada to Approved International Cannabis Countries

03/08/17 - ViaDerma, Inc. Hires Product Rollout Expert to Manage Quality Control Labeling, Marketing and Distribution of its Go to Market Product Line Launch

02/15/17 - ViaDerma, Inc. Looks to File Additional Patents & License New Products for its (MMJ) Medical Marijuana Patent Pending Delivery Technology with Licensed Dispensaries

02/08/17 - Dr. Chris Ayo Otiko, President of ViaDerma, Inc., is selected to write an article "Healing Diabetic Ulcers with a New Topical Antibiotic Ointment" for the Journal of Diabetes
Science and Technology, a leading US Publication for Diabetes


02/03/17 - ViaDerma, Inc. Targets Online Sales, Wound Care Centers and Distribution Companies for its Viabecline Product Launch, the First Viabecline Orders Set for Q2-2017,
also  Onychomycosis Clinical Studies Show Significant Results


01/11/17 - ViaDerma, Inc's CEO Files New Patent Application, Signs Two Licensing Deals, Locates Product Manufacturers in the US & Abroad, and Plans to add over 500 Affiliates Selling
Viabecline Through Established Online Distribution Networks in 2017


12/09/16 - Video with Dr. Otiko by Jasyn Blair of Uptick Newswire - Notes

 
VDRM
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PostSubject
#23732  Sticky Note It's pretty clear no one wants to sell freestock 06/16/17 12:12:30 PM
#23606  Sticky Note ViaDerma, Inc. Begins Consumer Testing on its Topical nygrande 06/15/17 11:04:52 AM
#23364  Sticky Note ViaDerma, Inc. Commences First Manufacturing Run and will Cryptocol 06/12/17 11:05:26 AM
#20971  Sticky Note $VDRM Confirmed with management that there will be Momostocktrades 05/01/17 08:01:32 AM
#20071  Sticky Note Keough paid Phillips $300,000.00 for full ownership rights Mistral 04/19/17 02:01:10 PM
#13415  Sticky Note EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/17 10:10:04 AM
#24011   does any member know if the diabetic foot madcasper 06/24/17 07:19:41 PM
#24010   https://heraldks.com/eps-for-hub-group-hubg-expected-at-0-40-viaderma-vdrm-si-de ABK_TLL 06/24/17 06:54:39 PM
#24009   Truth bomb!:-) kennyt 335 06/24/17 12:04:16 PM
#24008   How benevolent, you have no shares and decided ABK_TLL 06/24/17 12:00:05 PM
#24007   Yep.. These startups take some time to mature. Lambsheadranch 06/24/17 01:46:41 AM
#24005   10/30/2014 12:00PM PR Newswire (US) ViaDerma, Inc. Lead Product TetraStem Shown clicker lewis 06/23/17 09:07:15 PM
#24004   retired early .... Sorry spelled your name wrong sluggercjb 06/23/17 07:14:56 PM
#24003   Hello retired realy .... Your are one of sluggercjb 06/23/17 07:09:37 PM
#24002   $25K worth of shares ABK_TLL 06/23/17 05:09:37 PM
#24001   Thank you, Have a good weekend! MegaVerde 06/23/17 05:01:29 PM
#24000   In that case, I'll give you a pass...:) nsomniyak 06/23/17 05:00:00 PM
#23999   To be fair, I is been drinking... MegaVerde 06/23/17 04:59:20 PM
#23998   But grammar isn't. You should have written nsomniyak 06/23/17 04:56:28 PM
#23997   It's comical to see people say freestock 06/23/17 04:18:51 PM
#23996   About 25K shares traded today - u have ABK_TLL 06/23/17 04:04:05 PM
#23995   Green. MegaVerde 06/23/17 04:02:07 PM
#23994   HAHA! Punctuation and correct spelling is overrated! MegaVerde 06/23/17 03:49:48 PM
#23993   VDRM's IR probably does not respond to emails Clonefan 06/23/17 03:42:34 PM
#23992   thats why i sold also their clicker lewis 06/23/17 03:30:23 PM
#23991   VDRM should close a strong green, thinking .022-.023 dough11 06/23/17 02:54:09 PM
#23990   The biggest PR this company ever put out industrialist 06/23/17 02:43:47 PM
#23989   I'm going to spray the P.E and rub retired early 06/23/17 02:39:37 PM
#23988   .10 next leg up. retired early 06/23/17 12:59:42 PM
#23987   Well let's get down to earth 'l m freestock 06/23/17 12:46:38 PM
#23986   I agree,last PR said FDA registration numbers soon dough11 06/23/17 12:44:27 PM
#23985   vdrm is too going to explode as soon bullrunner7 06/23/17 12:11:49 PM
#23983   Not a lot of buying selling activity at Cryptocol 06/23/17 11:08:58 AM
#23982   Has crossed my mind in the past, who kennyt 335 06/23/17 11:07:45 AM
#23981   From Otikos correspondences with investors I believe him Cryptocol 06/23/17 11:06:07 AM
#23980   What if Keough and Otiko are working together Boogieflash 06/23/17 10:59:35 AM
#23979   The company either can't or won't say anything RJ693 06/23/17 10:56:06 AM
#23978   MUST SEE !!!! https://www.pacermonitor.com/public/case/21120838/Keough_v_Otiko_e Pstats 06/23/17 10:52:57 AM
#23977   Would be nice to see 26 today Cryptocol 06/23/17 10:44:02 AM
#23975   It does NOT make sense ENERGY2016 06/23/17 10:26:22 AM
#23974   I'm starting to think Keogh did this to Lucky Fellow 06/23/17 10:24:52 AM
#23972   Could not disagree more. A very poor explanation hghscurry 06/23/17 09:51:34 AM
#23971   The case update explained.... Rigamortis Raccoon 06/23/17 09:42:31 AM
#23970   "T trades" are used in the pinks to SchlumpyStock-Picker 06/22/17 07:14:05 PM
#23969   Yes. That doesn't mean that he's selling. Which hghscurry 06/22/17 06:17:09 PM
#23968   Hey hghscurry, CO422 06/22/17 06:15:15 PM
#23967   Could also be a bunch of sellers and ABK_TLL 06/22/17 06:01:43 PM
#23966   No I get that but the T trade hghscurry 06/22/17 05:57:48 PM
#23965   Thank you! This is appreciated... BennyKrueger 06/22/17 05:56:40 PM
#23964   you're article proves my point..."there are no after-market eagle-i 06/22/17 05:42:08 PM
#23963   I don't think you are correct. Here is hghscurry 06/22/17 05:36:39 PM
#23962   that 1 mil shares that was cleared after eagle-i 06/22/17 05:36:34 PM
#23961   That's the first time I've heard of a hghscurry 06/22/17 05:33:00 PM
#23960   more shares into the market...just have to hope eagle-i 06/22/17 05:31:24 PM
#23959   So how is it negative? hghscurry 06/22/17 05:18:35 PM
#23958   its not a positive thing...it's one of the eagle-i 06/22/17 05:13:53 PM
PostSubject